197 related articles for article (PubMed ID: 26573598)
1. Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus.
Jenkinson C; Elliott VL; Evans A; Oldfield L; Jenkins RE; O'Brien DP; Apostolidou S; Gentry-Maharaj A; Fourkala EO; Jacobs IJ; Menon U; Cox T; Campbell F; Pereira SP; Tuveson DA; Park BK; Greenhalf W; Sutton R; Timms JF; Neoptolemos JP; Costello E
Clin Cancer Res; 2016 Apr; 22(7):1734-1743. PubMed ID: 26573598
[TBL] [Abstract][Full Text] [Related]
2. Thrombospondin-2 is a Highly Specific Diagnostic Marker and is Associated with Prognosis in Pancreatic Cancer.
Peng HY; Chang MC; Hu CM; Yang HI; Lee WH; Chang YT
Ann Surg Oncol; 2019 Mar; 26(3):807-814. PubMed ID: 30569296
[TBL] [Abstract][Full Text] [Related]
3. Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer.
Capello M; Bantis LE; Scelo G; Zhao Y; Li P; Dhillon DS; Patel NJ; Kundnani DL; Wang H; Abbruzzese JL; Maitra A; Tempero MA; Brand R; Firpo MA; Mulvihill SJ; Katz MH; Brennan P; Feng Z; Taguchi A; Hanash SM
J Natl Cancer Inst; 2017 Apr; 109(4):. PubMed ID: 28376157
[TBL] [Abstract][Full Text] [Related]
4. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma.
Lin C; Wu WC; Zhao GC; Wang DS; Lou WH; Jin DY
Medicine (Baltimore); 2016 Aug; 95(31):e4527. PubMed ID: 27495108
[TBL] [Abstract][Full Text] [Related]
5. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
6. A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A case-control study.
Debernardi S; O'Brien H; Algahmdi AS; Malats N; Stewart GD; Plješa-Ercegovac M; Costello E; Greenhalf W; Saad A; Roberts R; Ney A; Pereira SP; Kocher HM; Duffy S; Blyuss O; Crnogorac-Jurcevic T
PLoS Med; 2020 Dec; 17(12):e1003489. PubMed ID: 33301466
[TBL] [Abstract][Full Text] [Related]
7. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease.
Shaw VE; Lane B; Jenkinson C; Cox T; Greenhalf W; Halloran CM; Tang J; Sutton R; Neoptolemos JP; Costello E
Mol Cancer; 2014 May; 13():114. PubMed ID: 24884871
[TBL] [Abstract][Full Text] [Related]
8. iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance.
Tonack S; Jenkinson C; Cox T; Elliott V; Jenkins RE; Kitteringham NR; Greenhalf W; Shaw V; Michalski CW; Friess H; Neoptolemos JP; Costello E
Br J Cancer; 2013 May; 108(9):1846-53. PubMed ID: 23579209
[TBL] [Abstract][Full Text] [Related]
9. Lower plasma levels of glucose-dependent insulinotropic peptide (GIP) and pancreatic polypeptide (PP) in patients with ductal adenocarcinoma of the pancreas and their relation to the presence of impaired glucoregulation and weight loss.
Škrha J; Bušek P; Uhrová J; Hrabal P; Kmochová K; Laclav M; Bunganič B; Frič P
Pancreatology; 2017; 17(1):89-94. PubMed ID: 28027898
[TBL] [Abstract][Full Text] [Related]
10. THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement.
Udgata S; Takenaka N; Bamlet WR; Oberg AL; Yee SS; Carpenter EL; Herman D; Kim J; Petersen GM; Zaret KS
Cancer Prev Res (Phila); 2021 Feb; 14(2):223-232. PubMed ID: 33067248
[TBL] [Abstract][Full Text] [Related]
11. Utility of serum CA19-9 levels in the diagnosis of pancreatic ductal adenocarcinoma in an endoscopic ultrasound referral population.
Parikh DA; Durbin-Johnson B; Urayama S
J Gastrointest Cancer; 2014 Mar; 45(1):74-9. PubMed ID: 24272911
[TBL] [Abstract][Full Text] [Related]
12. A Plasma Biomarker Panel to Identify Surgically Resectable Early-Stage Pancreatic Cancer.
Balasenthil S; Huang Y; Liu S; Marsh T; Chen J; Stass SA; KuKuruga D; Brand R; Chen N; Frazier ML; Jack Lee J; Srivastava S; Sen S; McNeill Killary A
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376184
[TBL] [Abstract][Full Text] [Related]
13. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
14. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
15. Phases of Metabolic and Soft Tissue Changes in Months Preceding a Diagnosis of Pancreatic Ductal Adenocarcinoma.
Sah RP; Sharma A; Nagpal S; Patlolla SH; Sharma A; Kandlakunta H; Anani V; Angom RS; Kamboj AK; Ahmed N; Mohapatra S; Vivekanandhan S; Philbrick KA; Weston A; Takahashi N; Kirkland J; Javeed N; Matveyenko A; Levy MJ; Mukhopadhyay D; Chari ST
Gastroenterology; 2019 May; 156(6):1742-1752. PubMed ID: 30677401
[TBL] [Abstract][Full Text] [Related]
16. Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma.
Yu J; Ploner A; Kordes M; Löhr M; Nilsson M; de Maturana MEL; Estudillo L; Renz H; Carrato A; Molero X; Real FX; Malats N; Ye W
Int J Cancer; 2021 Apr; 148(8):2048-2058. PubMed ID: 33411965
[TBL] [Abstract][Full Text] [Related]
17. Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma.
Wang X; Li Y; Tian H; Qi J; Li M; Fu C; Wu F; Wang Y; Cheng D; Zhao W; Zhang C; Wang T; Rao J; Zhang W
BMC Cancer; 2014 Aug; 14():578. PubMed ID: 25106741
[TBL] [Abstract][Full Text] [Related]
18. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
19. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.
Sharma A; Smyrk TC; Levy MJ; Topazian MA; Chari ST
Gastroenterology; 2018 Aug; 155(2):490-500.e2. PubMed ID: 29723506
[TBL] [Abstract][Full Text] [Related]
20. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]